Exact Sciences’ next-gen colorectal cancer test hits primary goals in pivotal study

A 20,000-subject clinical trial of Exact Sciences’ next-generation colorectal cancer test has met its primary endpoints, positioning the company to file to sell the diagnostic in the U.S. this year.